The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living heart valves or blood vessels, have been published in peer-reviewed journal Acta Biomaterialia.
Leading global experts in regenerative medicine from prestigious institutions analyzed preclinical data on Xeltis’ pulmonary valve to gain deeper understanding on the evolution and mechanisms of inflammation, polymer absorption and tissue regeneration involved in the ETR process.
Authors of the paper included among others: professor Carlijn Bouten and assistant professor Anthal Smits from the Soft Tissue Biomechanics and Tissue Engineering research group at Eindhoven University of Technology, Katja Schenke-Layland, professor of medical technologies and regenerative medicine at University Women’s Hospital Tübingen and Frederick J. Schoen, professor of pathology and health sciences and technology, Harvard Medical School and executive vice-chairman, department of pathology, Brigham and Women’s Hospital.
“The preclinical data from the Xeltis devices are tremendously valuable. We are proud that our collaborative research is helping grow the body of evidence explaining in situ heart valve engineering.”
said corresponding author Dr. Smits
